1015 Walnut Street
Suite 320
Philadelphia, PA 19107
(215) 955-5266 (Voice box 9-8686)
(215) 955-9170 fax
Suite 320
Philadelphia, PA 19107
(215) 955-5266 (Voice box 9-8686)
(215) 955-9170 fax
Most Recent Peer-reviewed Publications
- Aggregation of normal and sickle hemoglobin in high concentration phosphate buffer
- Gender-specific disease modification by NOS3 (multiple letters)
- Kinetics of increased deformability of deoxygenated sickle cells upon oxygenation
- Hydroxyurea analogues as kinetic and mechanistic probes of the nitric oxide producing reactions of hydroxyurea and oxyhemoglobin
- Urease enhances the formation of iron nitrosyl hemoglobin in the presence of hydroxyurea
Research and Clinical Interests
Dr. Ballas's laboratory has focused on studying the effects of the genetic features of sickle cell syndromes (α-genotype and β-haplotypes) on the cellular and clinical expression of the disease. Specific approaches included the determination of predictors of the severity of the disease, pathobiology of the disease, cellular changes during painful episodes, and the preventive therapy with Hydroxyurea - an inducer of fetal hemoglobin production. New novel approaches to therapy include aborting the acute painful episode by agents that reduce tissue ischemia and improve blood flow in the microvasculature.